{
    "nct_id": "NCT04995523",
    "official_title": "Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC",
    "inclusion_criteria": "* Written informed consent\n* Aged 18 or above\n* Part A and Part B: Unresectable stage III or stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation. Part C and Part D: Stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation. Part E: Stage IV squamous NSCLC not amenable to curative surgery or radiation.\n* Documented PD-L1 expression by PD-L1 IHC per local report.\n* Part A and Part B: Confirmed progression during treatment with a CPI-including regimen.\n* Part C and Part D: No prior I/O treatment for metastatic NSCLC.\n* Part E: No prior treatment for metastatic NSCLC.\n* ECOG performance status of 0 or 1 at enrolment.\n* Life expectancy of â‰¥ 12 weeks at enrolment.\n* Have at least 1 measurable lesion per RECIST v1.1.\n* Adequate bone marrow, liver and kidney function\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 130 Years",
    "exclusion_criteria": "* Sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) fusion\n* Documented test result for any other known genomic alteration for which a targeted therapy is approved in first line per local standard of care (e.g. ROS1, NTRK fusions, BRAF, V600E mutation)\n* Previous treatment with an anti-TIGIT therapy\n* Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment.\n* Part A and Part B: Primary or secondary resistance after treatment with 2 or more regiments including a CPI.\n* Part C and Part D: Any prior systemic treatment with an immune oncology agent (prior administration of immune-oncology agent for curative intent to treat other invasive malignancy is permitted).\n\nTreatment with one previous systemic chemotherapy will be allowed.\n\n* Part E: Any prior systemic treatment for metastatic NSCLC, including but not limited to chemotherapy, anti-PD-1, anti-PD-L1, anti-CTLA-4.\n* Symptomatic central nervous system (CNS) metastasis.\n* Thromboembolic event within 3 months prior to enrolment.\n* Other invasive malignancy within 2 years prior to screening.",
    "miscellaneous_criteria": ""
}